XORTX Therapeutics, a Canada-based late-stage clinical pharmaceutical company, has recently submitted a new patent for the treatment of chronic kidney disease (CKD). XORTX’s patent submission was supported by the efficacy and safety clinical data from a completed Phase II XRX-008 (oxypurinol) trial. If successful, it could be of high clinical value to physicians looking to find an optimal treatment of choice for individuals with varied stages of CKD, says GlobalData, a leading data and analytics company.

Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “According to the Epidemiology Database within GlobalData’s Pharma Intelligence Center (PIC), the number of total prevalent cases of chronic kidney disease in the US, France, Germany, Italy, Spain, the UK, and Japan is estimated to grow from approximately 105 million in 2023 to approximately 111 million in 2028.”

According to data from the Phase II trial, oxypurinol demonstrated a substantial increase in the bioavailability, improved dose proportionality, and achieved therapeutic target values.

In addition, no drug-related adverse or serious adverse events related to the oral administration of oxypurinol were shown. These conclusions potentially indicate that increased circulating concentrations of oxypurinol may inhibit uric acid production, thereby slowing down the progression of CKD.

The patent outlines new formulations and methods for safer and more effective use of xanthine oxidase inhibitors in treating CKD, particularly targeting autosomal dominant polycystic kidney disease, diabetic nephropathy, IgA nephropathy, lupus nephritis, and focal segmental glomerulosclerosis.

Jaddoo concludes: “According to GlobalData’s PIC Drug Database, XORTX has two other drugs in development: XRX-101 for acute kidney injury and XRX-225 for diabetic nephropathy.”